Expand all sections

Afatinib

Giotrif

Extended indication Head and neck (or upper airways tract) cancers, locally advanced (recurrent/metastatic) squamous cel
Therapeutic value No judgement
Total cost 48,480,000.00

Product

Active substance Afatinib
Domain Oncology and Hematology
Main indication Head and neck cancer
Extended indication Head and neck (or upper airways tract) cancers, locally advanced (recurrent/metastatic) squamous cell, 2nd line after platinum therapy
Proprietary name Giotrif
Manufacturer Boehringer Ingelheim
Route of administration Oral
Therapeutical formulation Tablet
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
Expected Registration 2021
Orphan drug No
Additional remarks Dit is een indicatie-uitbreiding. Al op de markt voor EGFR+ NSCLC, 1L en plaveiselcel NSCLC, 2L.

Therapeutic value

Current treatment options Methotrexate. Andere immunotherapiën en PD1/PDL1-remmers.
Therapeutic value No judgement
Duration of treatment Not found
Frequency of administration 1 times a day
Dosage per administration 40 mg

Expected patient volume per year

Patient volume

< 1,616

Market share is generally not included unless otherwise stated.
References NKR
Additional remarks NKR 2015: Hoofd-hals tumoren, stadium 3 en 4, respectivelijk 427 en 1189

Expected cost per patient per year

Cost < 30,000.00
References Medicijnkosten.nl; Fabrikant
Additional remarks Meerkosten. Huidige kosten giotrif: per tablet van 20/30/40/50mg is het €82,86. Meerkosten t.o.v. MTX. Fabrikant geeft aan dat Afatinib €26.256 pppj kost.

Potential total cost per year

Total cost

48,480,000.00

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.